Prognostic factors in patients with skeletal‑related events at non‑small‑cell lung cancer diagnosis

Tominaga,Hiroyuki; Setoguchi,Takao; Shimada,Hirofumi; Nagano,Satoshi; Sasaki,Hiromi; Ishidou,Yasuhiro; Sato,Masami; Mizuno,Keiko; Inoue,Hiromasa; Komiya,Setsuro

doi:10.3892/mco.2017.1394

Prognostic factors in patients with skeletal‑related events at non‑small‑cell lung cancer diagnosis

Authors:
- Hiroyuki Tominaga
- Takao Setoguchi
- Hirofumi Shimada
- Satoshi Nagano
- Hiromi Sasaki
- Yasuhiro Ishidou
- Masami Sato
- Keiko Mizuno
- Hiromasa Inoue
- Setsuro Komiya
View Affiliations

Affiliations: Department of Orthopaedic Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Kagoshima 890‑8520, Japan, The Near‑Future Locomotor Organ Medicine Creation Course (Kusunoki Kai), Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Kagoshima 890‑8520, Japan, Department of Medical Joint Materials, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Kagoshima 890‑8520, Japan, Department of General Thoracic Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Kagoshima 890‑8520, Japan, Department of Pulmonary Medicine, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Kagoshima 890‑8520, Japan
Published online on: August 25, 2017 https://doi.org/10.3892/mco.2017.1394
Pages: 897-902

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to detect prognostic factors in patients with skeletal‑related events (SREs) and bone metastasis at the time of non‑small‑cell lung cancer (NSCLC) diagnosis. A total of 85 NSCLC patients were retrospectively enrolled, 47 (55.2%) of whom presented with SREs at the time of NSCLC diagnosis. Multivariate logistic regression analysis identified squamous cell carcinoma as a risk factor for SRE. Kaplan‑Meier analysis demonstrated that there was no difference in the overall survival between the SRE and no SRE groups. Cox hazard model revealed that a higher Eastern Cooperative Oncology Group (ECOG) performance status (PS) score was a risk factor for poor prognosis, while surgery for bone metastasis and molecular‑targeted therapy were factors for better prognosis in patients with SREs at the time of NSCLC diagnosis. Multivariate analysis revealed that a higher ECOG PS score and metastasis to the adrenal gland were risk factors for poor prognosis, while surgery for bone metastasis and molecular‑targeted therapy were factors for better prognosis. Thus, while surgical treatment and molecular‑targeted therapy appear to improve the prognosis of patients with bone metastasis at the time of NSCLC diagnosis, those with a higher ECOG PS score and adrenal metastasis may benefit more from radiotherapy or supportive care.

View Figures

View References

1	Zeng X, Li J, Peng L, Wang Y, Tan C, Chen G, Wan X, Lu Q and Yi L: Economic outcomes of maintenance gefitinib for locally advanced/metastatic non-small-cell lung cancer with unknown EGFR mutations: A semi-Markov model analysis. PLoS One. 9:e888812014. View Article : Google Scholar : PubMed/NCBI
2	Rosen LS, Gordon D, Tchekmedyian NS, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, De Souza P, Zheng M, Urbanowitz G, et al: Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: A randomized, Phase III, double-blind, placebo-controlled trial. Cancer. 100:2613–2621. 2004. View Article : Google Scholar : PubMed/NCBI
3	He YF, Luo HQ, Wang W, Chen J, Yao YW, Cai SB, He J, Yan Y, Wu SS, Hu XX, et al: Clinical features and prognosis-associated factors of non-small cell lung cancer exhibiting symptoms of bone metastasis at the time of diagnosis. Oncol Lett. 9:2706–2712. 2015.PubMed/NCBI
4	Ulas A, Bilici A, Durnali A, Tokluoglu S, Akinci S, Silay K, Oksuzoglu B and Alkis N: Risk factors for skeletal-related events (SREs) and factors affecting SRE-free survival for nonsmall cell lung cancer patients with bone metastases. Tumour Biol. 37:1131–1140. 2016. View Article : Google Scholar : PubMed/NCBI
5	Santini D, Barni S, Intagliata S, Falcone A, Ferraù F, Galetta D, Moscetti L, La Verde N, Ibrahim T, Petrelli F, et al: Natural history of non-small-cell lung cancer with bone metastases. Sci Rep. 5:186702015. View Article : Google Scholar : PubMed/NCBI
6	Shimada H, Setoguchi T, Yokouchi M, Sasaki H, Ishidou Y, Kawamura I, Abematsu M, Nagano S and Komiya S: Metastatic bone tumors: Analysis of factors affecting prognosis and efficacy of CT and F-FDG PET-CT in identifying primary lesions. Mol Clin Oncol. 2:875–881. 2014. View Article : Google Scholar : PubMed/NCBI
7	Mirels H: Metastatic disease in long bones. A proposed scoring system for diagnosing impending pathologic fractures. 1989. Clin Orthop Relat Res. (415 Suppl):S4–S13. 2003. View Article : Google Scholar : PubMed/NCBI
8	Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET and Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
9	Wu M, Zhao J, Song SW, Zhuo M, Wang X, Bai H, Wang S, Yang L, An T, Zhang Y, et al: EGFR mutations are associated with prognosis but not with the response to front-line chemotherapy in the Chinese patients with advanced non-small cell lung cancer. Lung Cancer. 67:343–347. 2010. View Article : Google Scholar : PubMed/NCBI
10	Aggarwal C and Langer CJ: Older age, poor performance status and major comorbidities: How to treat high-risk patients with advanced nonsmall cell lung cancer. Curr Opin Oncol. 24:130–136. 2012. View Article : Google Scholar : PubMed/NCBI
11	Leprieur Giroux E, Lavole A, Ruppert AM, Gounant V, Wislez M, Cadranel J and Milleron B: Factors associated with long-term survival of patients with advanced non-small cell lung cancer. Respirology. 17:134–142. 2012. View Article : Google Scholar : PubMed/NCBI
12	Kalikaki A, Koutsopoulos A, Hatzidaki D, Trypaki M, Kontopodis E, Stathopoulos E, Mavroudis D, Georgoulias V and Voutsina A: Clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy according to EGFR and K-RAS mutation status. Lung Cancer. 69:110–115. 2010. View Article : Google Scholar : PubMed/NCBI
13	Leung EY, Scott HR and McMillan DC: Clinical utility of the pretreatment glasgow prognostic score in patients with advanced inoperable non-small cell lung cancer. J Thorac Oncol. 7:655–662. 2012. View Article : Google Scholar : PubMed/NCBI
14	Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, Vynnychenko I, Park K, Eberhardt WE, de Marinis F, et al: Prognostic factors in patients with advanced non-small cell lung cancer: Data from the phase III FLEX study. Lung Cancer. 77:376–382. 2012. View Article : Google Scholar : PubMed/NCBI
15	Zhang Y, Jin B, Shao M, Dong Y, Lou Y, Huang A and Han B: Monitoring of carcinoembryonic antigen levels is predictive of EGFR mutations and efficacy of EGFR-TKI in patients with lung adenocarcinoma. Tumour Biol. 35:4921–4928. 2014. View Article : Google Scholar : PubMed/NCBI
16	Duan JC, An TT, Wu MN, Yang L, Bai H, Wang ZJ, Wang YY, Zhuo ML, Zhao J, Wang SH and Wang J: Correlation between the efficacy of epidermal growth factor receptor tyrosine kinase inhibitors and EGFR mutations in advanced squamous cell lung cancer. Zhonghua Jie He He Hu Xi Za Zhi. 35:323–328. 2012.(In Chinese). PubMed/NCBI
17	Stetler-Stevenson WG: Type IV collagenases in tumor invasion and metastasis. Cancer Metastasis Rev. 9:289–303. 1990. View Article : Google Scholar : PubMed/NCBI
18	Mundy GR: Mechanisms of bone metastasis. Cancer. 80 (8 Suppl):S1546–S1556. 1997. View Article : Google Scholar
19	Tomita A, Kasaoka T, Inui T, Toyoshima M, Nishiyama H, Saiki H, Iguchi H and Nakajima M: Human breast adenocarcinoma (MDA-231) and human lung squamous cell carcinoma (Hara) do not have the ability to cause bone resorption by themselves during the establishment of bone metastasis. Clin Exp Metastasis. 25:437–444. 2008. View Article : Google Scholar : PubMed/NCBI
20	Coleman RE: Metastatic bone disease: Clinical features, pathophysiology and treatment strategies. Cancer Treat Rev. 27:165–176. 2001. View Article : Google Scholar : PubMed/NCBI
21	Coleman RE: Bisphosphonates: Clinical experience. Oncologist. 9 Suppl 4:S14–S27. 2004. View Article : Google Scholar
22	Cetin K, Christiansen CF, Jacobsen JB, Nørgaard M and Sørensen HT: Bone metastasis, skeletal-related events, and mortality in lung cancer patients: A Danish population-based cohort study. Lung Cancer. 86:247–254. 2014. View Article : Google Scholar : PubMed/NCBI
23	Bae HM, Lee SH, Kim TM, Kim DW, Yang SC, Wu HG, Kim YW and Heo DS: Prognostic factors for non-small cell lung cancer with bone metastasis at the time of diagnosis. Lung Cancer. 77:572–577. 2012. View Article : Google Scholar : PubMed/NCBI
24	Plones T, Osei-Agyemang T, Krohn A and Passlick B: Surgical treatment of extrapulmonary oligometastatic non-small cell lung cancer. Indian J Surg. 77 Suppl 2:S216–S220. 2015. View Article : Google Scholar
25	Chen YJ, Chang GC, Chen HT, Yang TY, Kuo BI, Hsu HC, Yang HW and Lee TS: Surgical results of metastatic spinal cord compression secondary to non-small cell lung cancer. Spine (Phila Pa 1976). 32:E413–E418. 2007. View Article : Google Scholar : PubMed/NCBI
26	Lei M, Liu Y, Tang C, Yang S, Liu S and Zhou S: Prediction of survival prognosis after surgery in patients with symptomatic metastatic spinal cord compression from non-small cell lung cancer. BMC Cancer. 15:8532015. View Article : Google Scholar : PubMed/NCBI
27	Niu FY, Zhou Q, Yang JJ, Zhong WZ, Chen ZH, Deng W, He YY, Chen HJ, Zeng Z, Ke EE, et al: Distribution and prognosis of uncommon metastases from non-small cell lung cancer. BMC Cancer. 16:1492016. View Article : Google Scholar : PubMed/NCBI
28	Urschel JD, Finley RK and Takita H: Long-term survival after bilateral adrenalectomy for metastatic lung cancer: A case report. Chest. 112:848–850. 1997. View Article : Google Scholar : PubMed/NCBI
29	Karolyi P: Do adrenal metastases from lung cancer develop by lymphogenous or hematogenous route? J Surg Oncol. 43:154–156. 1990. View Article : Google Scholar : PubMed/NCBI
30	Chadeyras JB, Mazel C and Grunenwald D: Vertebral en bloc resection for lung cancer: Twelve years' experience. Ann Chir. 131:616–622. 2006.(In French). View Article : Google Scholar : PubMed/NCBI